Effects of WB-EMS in Ulcerative Colitis Patients

Effects of Different Types of Whole Body Electromyostimulation (WB-EMS) Application on Body Composition, Muscle Strength and Quality of Life in Patients With Ulcerative Colitis

Status

Withdrawn

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02144129

Enrollment

Registered

2014-05-21

Start date

2014-03-31

Completion date

2018-01-31

Last updated

2018-01-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative Colitis

Keywords

Whole Body Electromyostimulation, Inflammatory Bowel Disease, Lean Body Mass, Muscle Strength

Brief summary

The purpose of this study is to determine the effect of 12 weeks of WB-EMS either applicated passive in a supine resting position or active during slight movements compared with a non-training control group on body composition, muscle strength and QoL in patients with ulcerative colitis. Our main hypothesis is that active WB-EMS application is significantly more favorable to address our primary endpoints compared with passive application. Our secondary hypothesis is that passive WB-EMS application is significantly more favorable to address our primary endpoints compared with non-training control.

Interventions

OTHERactive Whole Body Electromyostimulation

OTHERPassive WB-EMS

DEVICEWB-EMS application

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* ulcerative colitis * ambulatory subjects

Exclusion criteria

* variables that conflicts with WB-EMS application (e.g. cardiac pacemakers) * absence of more than two weeks during the interventional period.

Design outcomes

Primary

Measure	Time frame	Description
Lean Body Mass	12 weeks, baseline to 12 week follow-up	Lean Body Mass (LBM) and Appendicular Skeletal Muscle Mass (ASMM) as assessed by Dual-Energy-x-Ray Absorptiometry (DXA)
Isokinetic muscle strength	12 weeks, baseline to 12 week follow-up	Isokinetic muscle strength of the leg extensors and - flexors as assessed by a isokinetic leg strength

Secondary

Measure	Time frame	Description
Quality of Life (QoL)	12 weeks, baseline to 12 week follow-up	QoL as assessed by inflammatory bowel disease questionnaire (IBDQ-D) and Depression Scores
Isometric muscle strength	12 weeks, baseline 12 week follow-up	Isometric strength of the trunk flexors.

Other

Measure	Time frame	Description
Aerobic capacity	12 weeks, baseline to 12 weel follow-up	Aerobic capacity as assessed by 6 min walking test
Inflammatory Markers	12 weeks, baseline to 12 week follow-up	—

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026